Key result
Genetic sequencing identifies pathogenic variants in ~20% of Qatari HCM cases, including potential Arabic founder mutations.
Why the study?
The full spectrum of causative mutations for HCM and DCM remains to be discovered, particularly in understudied populations.
Observational (n=135)
Genetic evaluation of cardiomyopathy patients in Qatar reveals a 20% yield for pathogenic variants in HCM and 8% in DCM, identifying potential founder mutations in the Arab population.
Supports targeted genetic evaluation in Qatari cardiomyopathy; leaves open validation of founder mutations before wider adoption.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are serious inherited heart diseases with various causative mutations identified. The full spectrum of causative mutations remains to be discovered, especially in understudied populations. METHODS: Here, we established the DOHA Registry and Biobank for cardiomyopathies in Qatar, followed by sequencing of 174 genes on 51 HCM and 53 DCM patients, and 31 relatives. RESULTS: In HCM, the analysis of 25 HCM-associated genes showed that 20% of HCM cases had putative pathogenic variants for cardiomyopathy, mainly in sarcomere genes. Additional 49% of HCM cases had variants of uncertain significance, while 31% of HCM cases had likely benign variant(s) or had no variants identified within the analyzed HCM genes. In DCM, 56 putative DCM genes were analyzed. Eight percent of DCM cases had putative pathogenic variants for DCM, in the TTN gene while 70% of cases had variants of uncertain significance, in the analyzed DCM genes, that will need further pathogenicity assessment. Moreover, 22% of DCM cases remain unexplained, by having likely benign variant(s) or having no variants detected in any of the analyzed DCM genes. CONCLUSION: We identified or replicated at least four recurrent variants among cardiomyopathy patients, which could be founder disease mutations in the Arabic population, including a frameshift variant (c.1371_1381dupTATCCAGTTAT) of unknown significance in the FKTN gene which seems to cause DCM in homozygosity, and HCM in heterozygosity. In vivo and/or in vitro functional validation need to be pursued in order to assess the pathogenicity of the identified variants.
No takes yet. Share an insight, caveat, or question.
Al‐Shafai et al. (2021) conducted an observational in Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) (n=135). Genetic sequencing (174 genes) was evaluated on Identification of putative pathogenic variants. Genetic sequencing of cardiomyopathy patients in Qatar identified putative pathogenic variants in 20% of HCM cases and 8% of DCM cases, including potential founder mutations in the Arabic population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: